|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:trastuzumab
gptkb:trastuzumab-qyzy
|
|
gptkbp:activities
|
inhibits HE R2 signaling
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2006
gptkb:FDA
|
|
gptkbp:associated_with
|
improved response rates
|
|
gptkbp:can_be_used_with
|
chemotherapy
|
|
gptkbp:class
|
targeted therapy
|
|
gptkbp:clinical_trial
|
Phase III
various studies
|
|
gptkbp:combatants
|
high affinity for HE R2
|
|
gptkbp:contraindication
|
history of hypersensitivity
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:duration
|
depends on regimen
|
|
gptkbp:education
|
importance of adherence
|
|
gptkbp:effective_date
|
FDA approved
|
|
gptkbp:formulation
|
lyophilized powder
|
|
gptkbp:frequency
|
every 3 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
trastuzumab-dttb
|
|
gptkbp:impact
|
improves overall survival
|
|
gptkbp:indication
|
HE R2-positive breast cancer
|
|
gptkbp:influences
|
immune response
tumor growth
|
|
gptkbp:interacts_with
|
anthracyclines
|
|
gptkbp:involves
|
multidisciplinary care
|
|
gptkbp:is_available_on
|
prescription medication
|
|
gptkbp:is_monitored_by
|
cardiac function
|
|
gptkbp:is_used_for
|
treatment of breast cancer
|
|
gptkbp:manager
|
IV
|
|
gptkbp:marketed_as
|
gptkb:Herceptin
|
|
gptkbp:origin
|
humanized
|
|
gptkbp:pharmacokinetics
|
long half-life
inhibits cell proliferation
|
|
gptkbp:population
|
women with breast cancer
|
|
gptkbp:provides_information_on
|
NCCN guidelines
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
HE R2-targeted therapies
|
|
gptkbp:safety_features
|
during treatment
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
infusion reactions
cardiotoxicity
|
|
gptkbp:social_structure
|
Ig G1 monoclonal antibody
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
HE R2 protein
|
|
gptkbp:traded_on
|
gptkb:Herceptin
|
|
gptkbp:treatment
|
reduced recurrence rates
|
|
gptkbp:used_in
|
clinical practice
adjuvant therapy
neoadjuvant therapy
metastatic breast cancer
|
|
gptkbp:weight
|
148 k Da
|